In MS, iron rim lesions tied to severe disability, more brain damage
A team of scientists analyzed data from over a dozen studies involving more than 900 people with MS to research iron rim lesions.| Multiple Sclerosis News Today
A team of scientists analyzed data from over a dozen studies involving more than 900 people with MS to research iron rim lesions.| Multiple Sclerosis News Today
Rebif (interferon beta-1a) is a disease-modifying therapy for relapsing forms of MS. Learn about its uses, indications, and side effects.| Multiple Sclerosis News Today
Ibudilast was shown on MRI scans to slow the growth of chronic active lesions in the brains of progressive MS patients in the SPRINT-MS trial.| Multiple Sclerosis News Today
The presence of two distinct chronic lesion markers on MRI is linked to faster disability progression in MS patients, researchers say.| Multiple Sclerosis News Today
In MS, slowly expanding lesions were linked to more myelin loss in brain regions of damage and in normal-appearing brain tissue, per a study.| Multiple Sclerosis News Today
MRI is an imaging technique that can aid in diagnosing MS. Learn more about how this tool is used to detect MS and assess damage in the CNS.| Multiple Sclerosis News Today
MS is categorized into four main types: CIS, RRMS, SPMS, and PPMS. Learn more about each different type, their presentation, and treatment.| Multiple Sclerosis News Today
Several tests, including MRI and blood tests, can be used to diagnose MS. Learn more about testing and what to expect after a diagnosis.| Multiple Sclerosis News Today
With 17 piercings, columnist Desiree Lama had to find ways to accommodate annual MRIs, considering all the jewelry she wears.| Multiple Sclerosis News Today
The exact causes of MS are not known, but several factors, such as genetic factors, infection, and demographics, are linked to MS development.| Multiple Sclerosis News Today
In MS, the myelin sheath is damaged by the immune system's inflammatory attack. Learn more about its function and how it relates to MS.| Multiple Sclerosis News Today
Iaso Bio has received clearance from the FDA to start clinical trials to test its CAR T-cell therapy equecabtagene autoleucel in MS patients.| Multiple Sclerosis News Today
Many MS patients experience primary headaches, and disease-modifying therapies may play different roles in their development, per a study.| Multiple Sclerosis News Today
